ProteomEdge
Precision protein quantification standards for mass spectrometry.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $7.8m | Early VC | |
| Total Funding | 000k | ||
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 8925 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (148975 %) | (1507 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ProteomEdge is a Swedish life sciences company, founded in 2019 by researchers from the Human Protein Atlas program and the Science for Life Laboratory infrastructure. The company develops and provides proprietary analysis platforms for mass spectrometry, focusing on absolute quantification of blood plasma proteins for clinical and research applications.
The core of ProteomEdge's offering is its technology that uses cleavable heavy-isotope labeled protein standards. This method is designed to provide high accuracy in protein quantification and is delivered in a user-friendly format, such as pre-aliquoted and dried 96-well plates, which allows for simple, addition-only protocols suitable for automated pipelines. The business model centers on selling these proprietary products to researchers and scientists in the life sciences sector. Clients purchase specific protein analysis panels and related data, including lot-specific details, protocols, and peptide libraries accessible via the company's website.
The company's co-founder is Professor Mathias Uhlén, who serves as the Chairman of the Board. In a recent development, ProteomEdge secured 7.8 million SEK in a funding round led by Navigare Ventures to accelerate commercialization. Concurrently, Dr. Henrik Everberg was appointed as the new full-time CEO, effective August 2025, succeeding Dr. Marianne Hansson. ProteomEdge has been actively launching new products, including ApoEdge™ in November 2023, DiscoveryEdge™175 in April 2024, ComplemEdge in June 2024, and LiverEdge in August 2024, with more panels in the pipeline.
Keywords: absolute protein quantification, mass spectrometry, proteomics, blood plasma proteins, protein standards, Human Protein Atlas, life sciences, biomarker discovery, clinical research, diagnostic tools, biopharma, healthtech, cleavable standards, multiplexed analysis, apolipoproteins, complement factors, liver biomarkers, precision medicine, next-generation blood profiling, bioinformatics platforms.